Figure 5.

Immunocytochemical expression of SIRT1 and SIRT2 in breast cancer cells after compound treatment and docking study between SIRT2 and 5b. MCF-7 and MDA-MB-231 cells were treated with 50 μM of Sirtinol and 4 μM of 5b for 24 h and fixed for immunocytochemical analysis of SIRT1 and SIRT2. (A-B) Reduced expression of cytoplasmic localized SIRT1 was observed after 5b treatment. Images were taken by using 60X oil objective under confocal microscope. Bar scale represents here 10 µM. (C-D) Diminished level of SIRT2 was observed after incubation with Sirtinol and 5b. Bars represent 10 µM. (E) Molecular modeling showed binding between 5b and SIRT2 (with different amino acids residues). Figure showed receptor-ligand Hydrogen bonds (Green) and Receptor-ligand bumps of 5b with active site residues of SIRT2 protein.